The value (monetary amount) of the award the plaintiff seeks in the legal matter.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Legal Matters - Narrative (Details) - Pending Litigation € in Thousands	Sep. 26, 2016 EUR (€)	Apr. 01, 2019 claim	Feb. 25, 2019 claim
Amgen v.s. Regeneron
Loss Contingencies [Line Items]
Loss contingency, damages sought, per unit produced \| €	€ 10
Loss contingency, damages sought \| €	€ 10,000
'165 Patent \| Amgen v.s. Regeneron
Loss Contingencies [Line Items]
Pending claims			2
Invalid claims			2
'741 Patent \| Amgen v.s. Regeneron
Loss Contingencies [Line Items]
Pending claims			1
Subsequent Event \| '688 Patent
Loss Contingencies [Line Items]
Pending claims		1
Asserted claims		9